Healthy Volunteers Clinical Trial
— ALVOPADOfficial title:
Single Centre, Randomised, Single-Blind, Pilot Study to Compare the Safety, Tolerability and Pharmacokinetics of AVT02 to EU-approved Humira® as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adult Subjects (ALVOPAD)
Verified date | January 2019 |
Source | Alvotech Swiss AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Adalimumab is an immunosuppressive drug that belongs to the family of anti-TNF agents. It
contains a monoclonal antibody produced by biotechnology. It is designed to bind to tumor
necrosis factor (TNF), a substance that is involved in several auto-immune processes. By
binding to TNF, adalimumab blocks its activity, reducing the severity of various chronic
inflammatory diseases including Rheumatoid Arthritis, Plaque Psoriasis and others.
Often, the high cost of biologic products may preclude access to the treatment to a big
portion of the population worldwide. A biosimilar product that provides comparable safety and
efficacy at more affordable cost would fulfill a broader medical need.
Humira has been available on the market for several years. Recently, a higher concentration
(100 mg/mL) formulation has been introduced in major markets. Alvotech is developing AVT02,
that is a proposed biosimilar of adalimumab containing high concentration (100 mg/mL) of
active ingredient.
The objective of this clinical trial is to assess the similarity of AVT02 (100 mg/mL) with
Humira (100 mg/mL), in terms of tolerability, safety (including immunogenicity) and compare
the pharmacokinetics in healthy volunteers.
Status | Completed |
Enrollment | 24 |
Est. completion date | August 24, 2018 |
Est. primary completion date | August 24, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Main Inclusion Criteria: - Male and female healthy adult subjects willing to sign an Informed Consent Form and able to undergo protocol related procedures. - Age: 18 to 55 years, inclusive. - Body Mass Index (BMI): 19.0 to 30.0 kg per m2. - Medical history without major pathology, at the discretion of Principal Investigator. - Resting supine systolic blood pressure of =150 mmHg and diastolic blood pressure of =90 mmHg. Other vital signs showing no clinically relevant deviations according to the Principal Investigator's judgment. - Computerised 12-lead ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the Principal Investigator. - Subjects who do not smoke tobacco products or use nicotine replacement therapy or e-cigarettes. Main Exclusion Criteria: - Evidence of clinically relevant pathology. - Unable to follow protocol instructions in the opinion of the Principal Investigator. - History of relevant drug and or food allergies. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study. - Known history of previous exposure to adalimumab or other anti-TNF-alpha molecules. - Any past or concurrent medical conditions potentially increasing the subject's risks, or would have interfered with the study evaluation, procedures, or study completion. Examples of these include medical history with evidence of clinically relevant pathology (e.g., malignancies, demyelinating disorders, herpes zoster, or hepatic, gallbladder or pancreatic diseases). - Presence of chronic obstructive pulmonary disease. Asthma in the childhood is allowed. - Evidence of a recent, within 6 months, infection requiring hospitalisation or intravenous antibiotic use. - Subject has a positive test for Tuberculosis (TB) during screening or a known history of active or latent TB, except documented and complete adequate treatment of TB. - Having received live vaccines during the 4 weeks before screening or have the intention to receive vaccination during the study. - Positive for Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HbcAb), anti- Hepatitis C virus antibodies (HCV), or anti-human immunodeficiency virus (HIV) 1 on 2 antibodies at screening. - Impaired liver function - Any persons who are an employee of the Principal Investigator, clinical centre, clinical research organisation or Sponsor, a relative of an employee of the clinical centre, the Investigator, Clinical Research Organization (CRO) or the Sponsor. - Other inclusion/exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Australia | Nucleus Network | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
Alvotech Swiss AG |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline blood pressure at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing | Measurement of blood pressure (systolic and diastolic in mm Hg) | Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing | |
Primary | Change from baseline heart rate at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing | Measure of heart rate (beats per minute) | Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing | |
Primary | Change from baseline body temperature at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing | Measurement of oral temperature (Celsius degree) | Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing | |
Primary | Change from baseline electrocardiogram at 1, 2, 5, 9, 64 days post dosing | Analysis of 12-lead electrocardiogram | Predose and 1, 2, 5, 9, 64 days post dosing | |
Primary | Change from baseline red blood cells at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure red blood cells count, (unit/mm3) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline haemoglobin at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure haemoglobin (g/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline white blood cells at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure white blood cells count, (unit/mm3) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline platelets at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure platelets count, (unit/mm3) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood gamma glutamyl transferase at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure gamma glutamyl transferase (UI/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood aspartate aminotransferase at 2, 3, 5, 9, 64 days post | Blood collection to measure aspartate aminotransferase (UI/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood alanine aminotransferase at 2, 3, 5, 9, 64 days post | Blood collection to measure alanine aminotransferase (UI/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood potassium at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure potassium (mmol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood sodium at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure sodium (mmol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood calcium at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure calcium (mmol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood phosphate at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure phosphate (mmol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood chloride at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure chloride (mmol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood bicarbonate at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure bicarbonate (mmol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood creatinine at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure creatinine (micromol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline blood bilirubin at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure Bilirubin (micromol/L) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline international normalised ratio at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure international normalised ratio | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline prothrombin time at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure prothrombin time (sec) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline partial prothrombin time at 2, 3, 5, 9, 64 days post dosing | Blood collection to measure partial prothrombin time (sec) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline activated partial thromboplastin time at 2, 3, 5, 9, 64 days post | Blood collection to measure activated partial thromboplastin time (sec) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline thrombin time at 2, 3, 5, 9, 64 days post | Blood collection to measure thrombin time (sec) | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline urine leucocytes at 2, 3, 5, 9, 64 days post dosing | Urine sample collection to measure leucocytes | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline urine glucose at 2, 3, 5, 9, 64 days post dosing | Urine sample collection to measure glucose | Predose and 2, 3, 5, 9, 64 days post dosing | |
Primary | Change from baseline urine protein at 2, 3, 5, 9, 64 days post dosing | Urine sample collection to measure protein | Predose and 2, 3, 5, 9, 64 days post dosing | |
Secondary | Area under the plasma concentration-time curve (AUC) | Venous blood samples will be collected for measurement of Area under the plasma concentration-time curve (AUC) of AVT02 and EU Humira | Over 64 days | |
Secondary | Maximum serum concentration | Venous blood samples will be collected for measurement of serum concentration of AVT02 and EU Humira | Over 64 days | |
Secondary | Time to maximum serum concentration | Evaluation of time to maximum plasma concentration (Tmax) of AVT02 and Humira. | Over 64 days | |
Secondary | Terminal half-life | Evaluation of terminal elimination half-life (T1/2) of AVT02 and Humira | Over 64 days | |
Secondary | Volume of distribution | Evaluation of volume of distribution during the elimination phase (Vz) of AVT02 and Humira | Over 64 days | |
Secondary | Clearance | Evaluation of total plasma clearance (CL) of AVT02 and Humira | Over 64 days | |
Secondary | Incidence and titer of anti-drug antibodies to adalimumab | A blood sample will be collected to measure antibodies to AVT02 and Humira | 15, 29 and 64 days after dosing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |